Patents by Inventor JEN-YAU CHEN

JEN-YAU CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089753
    Abstract: A method for treating cancer in a subject having a tumor in provided. The method includes administering to the subject a plurality of first dosages, each containing a peptide that comprises a sequence containing SEQ ID NO. 1 and is capable of selectively binding to CXC chemokine receptor 4 (CXCR4); and separately administrating to the subject a plurality of second dosages separately contained from the first dosages, the plurality of second dosages containing an immunotherapeutic agent for treating cancer, wherein the immunotherapeutic agent is an antibody that targets at least one of PD-1, PD-L1, TIM-3, LAG-3, B7-1, B7-H3, NKG2A, KIR, BTLA, VISTA/PD-1H, TIGIT, CD96, OX40, CD28, ICOS, HVEM, 41BB, CD40L, CD137, GITR, CD27, CD30, DNAM-1, CD28H and coreceptors thereof.
    Type: Application
    Filed: September 9, 2021
    Publication date: March 24, 2022
    Inventors: YA-CHUN WANG, JEN-YAU CHEN
  • Patent number: 11147832
    Abstract: The present disclosure provides a use of pentosan polysulfate sodium (PPS) in the manufacture of a medicament for the prevention of recurrent urinary tract infection (rUTI) in a human subject, comprising a therapeutically effective dosage for oral administration of PPS, wherein the therapeutically effective dosage for oral administration of PPS is 5-1 mg/kg/day.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: October 19, 2021
    Assignee: TCM BIOTECH INTERNATIONAL CORP.
    Inventors: Ya-Chun Wang, Yu-Ching Chang, Hsiao Tien Ma, Jen-Yau Chen, Yuan-Ju Lee, En Meng, Shang-Jen Chang
  • Publication number: 20200338115
    Abstract: The present disclosure provides a use of pentosan polysulfate sodium (PPS) in the manufacture of a medicament for the prevention of recurrent urinary tract infection (rUTI) in a human subject, comprising a therapeutically effective dosage for oral administration of PPS, wherein the therapeutically effective dosage for oral administration of PPS is 5-1 mg/kg/day.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 29, 2020
    Inventors: YA-CHUN WANG, YU-CHING CHANG, HSIAO TIEN MA, JEN-YAU CHEN, YUAN-JU LEE, EN MENG, SHANG-JEN CHANG
  • Publication number: 20190233524
    Abstract: A therapeutic combination for treating cancer in a subject having a tumor in provided. The therapeutic combination includes an immunotherapeutics for treating the cancer, and a peptide having one of SEQ ID NOs. 1-3 and being capable of selectively binding to CXC chemokine receptor 4 (CXCR4). When the peptide of the therapeutic combination binds to CXCR4, an immune microenvironment of the tumor is modulated and/or accessibility of immune cells to the tumor is regulated. A method for treating cancer using the therapeutic combination is also provided.
    Type: Application
    Filed: September 14, 2018
    Publication date: August 1, 2019
    Inventors: YA-CHUN WANG, JEN-YAU CHEN